News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

BrainStorm Cell Reports Third Quarter 2016 Financial Results

11/15/2016 10:50:46 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 15, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter ended September 30, 2016.

BrainStorm Cell Therapeutics

The CEO and senior management will host a corporate update call with shareholders in December (exact date and details will be published in a separate announcement). 

Third Quarter 2016 and Recent Highlights

  • On July 18, Brainstorm announced positive top line data from a double-blind, placebo controlled multi-center Phase 2 clinical trial evaluating NurOwn® in amyotrophic lateral sclerosis (ALS) patients.
    • The study achieved its primary objective, demonstrating that NurOwn® was safe and well tolerated.
    • NurOwn® also achieved multiple secondary efficacy endpoints, showing clear evidence of a clinically meaningful benefit.
    • Response rates were higher for NurOwn® treated subjects compared to placebo at all time points in the study out to 24 weeks.
    • The study was conducted at the Massachusetts General Hospital in Boston, at the University of Massachusetts Memorial Hospital in Worcester, Massachusetts and at the Mayo Clinic in Rochester, Minnesota.
  • On October 31, the Company announced that it was granted United States Patent No. 9,474,787 covering its stem cell technology.   This patent is the result of Brainstorm's ongoing joint development of NurOwn® together with the Tel Aviv University.

Financial Results for the Third Quarter Ended September 30, 2016

  • Total cash on hand $11.2M: A of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.   
  • Research and development expenses, net for the third quarter were $790,000 compared with $1.5 million for the third quarter 2015.  This decrease was due primarily to a decrease in costs of activities related to the U.S. Phase 2 clinical trial which were winding down in the third quarter of 2016.
  • General and administrative expenses for the third quarter were $848,000 and compared with $1.1 million in the third quarter of 2015.  The decrease was primarily due to a decrease in stock-based compensation expenses and payroll costs.
  • Financial income was $32,000 for the third quarter 2016, as compared to financial expenses of $32,000 for the third quarter 2015.
  • Net loss for the third quarter was $1.6 million or ($0.09) per share as compared to a net loss of $2.6 million or ($0.14) per share for the third quarter of 2015.

Financial Results for the Nine Months Ended September 30, 2016

  • Research and development expenses for the nine months ended September 30, 2016 were $1.9 million, compared to $4.1 million in the same period of 2015.
  • General and administrative expenses for the nine months ended September 30, 2016 were approximately $2.5 million, compared to $3.0 million in the same period of 2015.
  • Loss from operations for the nine months ended September 30, 2016 was $4.4 million, compared to $7.1 million in the same period of 2015.
  • Net loss for the nine months ended September 30, 2016 was $4.4 million, or ($0.23) per share, compared to a net loss of $7.1 million, or ($0.39) per share in the same period of 2015.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo.  For more information, visit the company's website at

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. 

To read full press release, please click here.

Read at

comments powered by Disqus